APOL1 Nephropathy: From Genetics to Clinical Applications.
Friedman DJ, Pollak MR.
Clin J Am Soc Nephrol. 2021 Feb 8;16(2):294-303. doi: 10.2215/CJN.15161219. Epub 2020 Jul 2.
Abnormal lipoprotein metabolism in diabetic nephropathy.
Hirano T.
Clin Exp Nephrol. 2014 Apr;18(2):206-9. doi: 10.1007/s10157-013-0880-y. Epub 2013 Oct 17.
Lipoprotein abnormalities in diabetic nephropathy.
Hirano T.
Kidney Int Suppl. 1999 Jul;71:S22-4. doi: 10.1046/j.1523-1755.1999.07106.x.
Nuclear Magnetic Resonance-Based Metabolomics and Risk of CKD.
Geng TT, Chen JX, Lu Q, Wang PL, Xia PF, Zhu K, Li Y, Guo KQ, Yang K, Liao YF, Zhou YF, Liu G, Pan A.
Am J Kidney Dis. 2024 Jan;83(1):9-17. doi: 10.1053/j.ajkd.2023.05.014. Epub 2023 Sep 9.
Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.
Szymanski JM, Waldman M, Conry-Cantilena C, West KA.
J Clin Apher. 2019 Aug;34(4):495-498. doi: 10.1002/jca.21677. Epub 2018 Dec 10.
Lipoprotein metabolism and CKD: overview.
Barter P.
Clin Exp Nephrol. 2014 Apr;18(2):243-6. doi: 10.1007/s10157-013-0866-9. Epub 2013 Sep 20.
APOL1 Nephropathy Risk Variant Associations with Diseases beyond the Kidney: APOL1 and Sepsis.
Ma L, Freedman BI.
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1684-1686. doi: 10.2215/CJN.10550919. Epub 2019 Nov 8.
Monocyte to High-Density Lipoprotein Ratio and Contrast-Induced Nephropathy.
Karanfil M, Yayla Ç, Ertem AG, Unal S, Açar B.
Angiology. 2018 Nov;69(10):917. doi: 10.1177/0003319718782537. Epub 2018 Jun 18.
Lipoprotein metabolism and renal failure.
Attman PO, Samuelsson O, Alaupovic P.
Am J Kidney Dis. 1993 Jun;21(6):573-92. doi: 10.1016/s0272-6386(12)80030-8.
APOL1 Nephropathy Risk Variants Through the Life Course: A Review.
Itoku A, Isaac J, Wilson S, Reidy K, Kaskel F.
Am J Kidney Dis. 2024 Jul;84(1):102-110. doi: 10.1053/j.ajkd.2023.12.014. Epub 2024 Feb 9.
